长链非编码RNA MEG3在甲状腺乳头状癌中的表达及与临床预后关系

摘要/Abstract

摘要： 目的研究甲状腺乳头状癌患者中的长链非编码RNA MEG3的表达,并探讨其与患者临床病理特征及预后的关系。方法纳入2020年4月—2022年3月在潍坊市中医院接受甲状腺乳头状癌治疗的78例患者为研究对象。手术中收集患者的癌组织和癌旁组织（距离癌组织边缘>1 cm）,采用荧光定量PCR检测lncRNA MEG3在癌组织及癌旁组织中的表达水平。随访患者术后24个月,收集并分析临床资料和病理特征。通过受试者工作特征（ROC）曲线评估MEG3对甲状腺乳头状癌的预测价值,使用Kaplan-Meier分析患者的2年生存情况,进行多因素Logistics回归分析以确定影响甲状腺乳头状癌预后不良的因素。结果甲状腺乳头状癌患者MEG3表达水平低于对照组,差异有统计学意义（P<0.05）;MEG3表达水平与甲状腺乳头状癌患者肿瘤分化程度、TNM分期、淋巴结转移有关（P<0.05）,与患者性别、年龄、肿瘤直径、病灶个数无关（P>0.05）,预后不良组MEG3表达水平低于预后良好组,差异有统计学意义（P<0.05）。MEG3诊断甲状腺乳头状癌的ROC曲线下面积为0.882,诊断灵敏度为82.1%,特异度为79.5%。MEG3高表达患者生存率高于MEG3低表达患者,差异有统计学意义（P<0.05）。MEG3低表达、肿瘤低分化、TNM分期Ⅲ~Ⅳ期、有淋巴结转移是影响甲状腺乳头状癌患者预后不良的独立危险因素（P<0.05）。结论 MEG3在甲状腺乳头状癌患者中低表达,可能参与甲状腺乳头状癌的发生及发展过程,是影响甲状腺乳头状癌患者预后的独立危险因素,可作为甲状腺乳头状癌预后评价的潜在标志物。

关键词: 甲状腺乳头状癌, lncRNA MEG3, 临床特征, 预后

Abstract: Objective To investigate the expression level of long non-coding RNA MEG3 in patients with papillary thyroid carcinoma (PTC) and its relationship with clinicopathological features and prognosis. Methods A total of 78 patients who were treated for papillary thyroid cancer in my Hospital from April 2020 to March 2022 were selected as the study objects. Cancer tissue and para-cancer tissue (distance from the edge of cancer tissue>1cm) were taken from patients during operation; lncRNA MEG3 expression levels were detected by fluorescence quantitative PCR. The PTC patients were followed up for 24 months. Clinical data and clinicopathological features of patients were collected and analyzed. Receiver operating characteristic (ROC) curve was used to analyze the predictive value of MEG3 on PTC patients Kaplan-Meier and multi-factor Logistics regression analysis were used to analyze the 3-year survival of patients and the factors affecting the poor prognosis of PTC. Results MEG3 expression level in patients with PTC was lower than that in control group , and the difference was statistically significant (P<0.05); The expression level of MEG3 was correlated with tumor differentiation, TNM stage and lymph node metastasis in PTC patients (P<0.05), was not related to patient gender, age, tumor diameter, number of lesions (P>0.05), the MEG3 expression level in the poor prognosis group was lower than that in the favourable prognosis group , and the difference was statistically significant (P<0.05). The area under ROC curve of MEG3 for the diagnosis of thyroid papillary carcinoma was 0.882, the diagnostic sensitivity was 82.1%, and the specificity was 79.5%. The survival rate of patients with high MEG3 expression was significantly higher than that of patients with low MEG3 expression. Low MEG3 expression, low tumor differentiation, TNM stage Ⅲ-Ⅳ, and lymph node metastasis were independent risk factors for poor prognosis in patients with papillary thyroid carcinoma (P<0.05). Conclusion MEG3 is low expression in patients with PTC, which may be involved in the occurrence and development of PTC. MEG3 is an independent risk factor affecting the prognosis of patients with PTC, and can be used as a potential marker for the prognosis evaluation of PTC.

Key words: papillary thyroid carcinoma, lncRNA MEG3, clinical features, prognosis

中图分类号:

R737.9

陈颖, 段文平, 王芳芳, 武希江, 黄婷婷, 张凤英. 长链非编码RNA MEG3在甲状腺乳头状癌中的表达及与临床预后关系[J]. 中华养生保健, 2025, 43(10): 7-11.

CHEN Ying, DUAN Wen-ping, WANG Fang-fang, WU Xi-jiang, HUANG Ting-ting, ZHANG Feng-ying. Expression of Long Non-Coding RNA MEG3 in Papillary Thyroid Carcinoma and Its Relationship with Clinical Prognosis[J]. ZHONGHUA YANGSHENG BAOJIAN, 2025, 43(10): 7-11.

参考文献

[1] SEIB C D,SOSA J A.Evolving understanding of the epidemiology of thyroid cancer[J].Endocrinol Metab Clin N Am,2019,48(1):23-35.
[2] XING M Z,ALZAHRANI A S,CARSON K A,et al.Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer[J].JAMA,2013,309(14):1493-1501.
[3] NICHOLSON K J,YIP L.An update on the status of molecular testing for the indeterminate thyroid nodule and risk stratification of differentiated thyroid cancer[J].Curr Opin Oncol,2018,30(1):8-15.
[4] HAN M A,KIM J H.Diagnostic X-ray exposure and thyroid cancer risk:systematic review and meta-analysis[J].Thyroid,2018,28(2):220-228.
[5] LEE J T.Epigenetic Regulation by Long Noncoding RNAs[J].Science,2012,338,1435-1439.
[6] HUARTE M.The Emerging Role of lncRNAs in Cancer[J].Nat Med,2015,21:1253-1261.
[7] TRIPATHI V,ELLIS J D,SHEN Z,et al.The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation[J].Mol Cell,2010,39:925-938.
[8] MIYOSHI N,WAGATSUMA H,WAKANA S,et al.Identification of an imprinted gene,Meg3 /Gtl2 and its human homologue MEG3,first mapped on mouse distal chromosome 12 and human chromosome 14q[J].Genes Cells,2000,5(3):211-220.
[9] LUO G,WANG M,WU X,et al.Long non-coding RNA MEG3 inhibits cell proliferation and induces apoptosis in prostate cancer[J].Cell Physiol Biochem,2015,37(6):2209-2220.
[10] ZHU J,LIU S,YE F,et al.Long non-coding RNA MEG3 interacts with p53 protein and regulates partial p53 target genes in hepatoma cells[J].PLoS One,2015,10(10) :e0139790.
[11] WANG X X,GUO G C,QIAN X K,et al.miR-506 attenuates methylation of lncRNA MEG3 to inhibit migration and invasion of breast cancer cell lines via targeting SP1 and SP3[J].Cancer Cell Int,2018,25(18):171.
[12] Yan J,Guo X,Xia J,et al.MiR-148a regulates MEG3 in gastric cancer by targeting DNA methyltransferase 1[J].Med Oncol,2014,31(3):879.
[13] 张清华,王瑞华,卓宜盟.甲状腺癌的诊断治疗[J].中国普通外科杂志,2010,19(11):1169-1172.
[14] COLE A M,PFLUGEISEN B,SCHWARTZ M R,et al.Cross sectional study to assess the accuracy of electronic health record data to identify patients in need of lung cancer screening[J].BMC Res Notes,2018,11:14.
[15] FAGIN J A,WELLS S A,Jr.Biologic and clinical perspectives on thyroid cancer[J].N Engl J Med,2016,375:1054-1067.
[16] GREWAL R K,HO A,SCHODER H.Novel approaches to thyroid cancer treatment and response assessment[J].Semin Nucl Med,2016,46:109-118.
[17] American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer,COOPER D S,DOHERTY G M, et al.Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J].Thyroid,2009,19:1167-1214.
[18] PACINI F,CASTAGNA M G.Approach to and treatment of differentiated thyroid carcinoma[J].Med Clin North Am,2012,96:369-383.
[19] GRANT C S.Recurrence of papillary thyroid cancer after optimized surgery[J].Gland Surg,2015,4:52-62.
[20] SCHNEIDER D F,CHEN H.New developments in the diagnosis and treatment of thyroid cancer[J].CA Cancer J Clin,2013,63:374-394.
[21] ZHOU Y,ZHANG X,KLIBANSKI A.MEG3 non-coding RNA:A tumor suppressor[J].J Mol Endocrinol,2012,48(3):R45-R53.
[22] BALIK V,SROVNAL J,SULLA I,et al.MEG3:a novel long noncoding potentially tumour-suppressing RNA in meningiomas[J].J Neurooncol,2013,112(1):1-8.
[23] JIA L F,WEI S B,GAN Y H,et al.Expression,regulation and roles of miR-26a and MEG3 in tongue squamous cell carcinoma[J].Int J Cancer,2014,135:2282-2293.
[24] LU K H,LI W,LIU X H,et al.Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression[J].BMC Cancer,2013,13:461.
[25] RIBARSKA T,GOERING W,DROOP J,et al.Deregulation of an imprinted gene network in prostate cancer[J].Epigenetics,2014,9:704-717.
[26] YING L,HUANG Y,CHEN H,et al.Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer[J].Mol Biosyst,2013,9:407-411.
[27] WANG C,YAN G,ZHANG Y,et al.Long non-coding RNA MEG3 suppresses migration and invasion of thyroid carcinoma by targeting of Rac1[J].Neoplasma,2015,62:541-549.